Conference Report

Breakthroughs in Cancer Research 2009

Source: CCO Independent Conference Coverage of the 2009 American Association for Cancer Research Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Breakthroughs in Cancer Research 2009

Faculty:

Roy S. Herbst, MD, PhD
Manuel Hidalgo, MD, PhD

CREDIT INFORMATION

Release Date: 07/07/09

Expiration Date: 07/06/10

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review the implications of new data suggesting prognostic significance of selected genetic alterations in malignancies such as pediatric acute lymphoblastic leukemia
Describe biological markers with the potential to predict response to treatment with targeted therapeutic agents in various tumor types
Recognize the utility of magnetic resonance imaging in predicting response to therapy in patients with glioblastoma
Discuss the feasibility of applying molecular profiling of refractory tumors to identify targets for therapy

Topics covered include:

Identification of JAK Mutations in Relapsed Pediatric ALL
Genetic Markers Associated With an Impaired Response to EGFR Inhibitors in mCRC
Validation of Ovarian Cancer Biomarkers for Early Screening
Molecular Profiling of Refractory Tumors to Identify Targets for Therapy
Inherited DICER1 Mutations in Familial Pleuropulmonary Blastoma
Use of Imaging Analysis in Glioblastoma to Predict Treatment Response
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.